Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition

(2014) William T. Cefalu   JOURNAL OF CLINICAL INVESTIGATION

The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate

(2014) Steven Woloshin et al.   JAMA Internal Medicine

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity

(2013) Manuel de Lera Ruiz et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Melanocortin 4 Receptors Reciprocally Regulate Sympathetic and Parasympathetic Preganglionic Neurons

(2013) Jong-Woo Sohn et al.   CELL

Microsomal transfer protein inhibition in humans

(2013) Marina Cuchel et al.   CURRENT OPINION IN LIPIDOLOGY

Long-term Drug Treatment for Obesity

(2013) Susan Z. Yanovski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

(2013) Shannon M Reilly et al.   NATURE MEDICINE

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

(2013) Harold E. Bays et al.   Obesity

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults

(2013) Louis J. Aronne et al.   Obesity

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

(2013) Anita Kapur et al.   BMC Pharmacology & Toxicology

Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques

(2012) P. Kievit et al.   DIABETES

A review of late-stage CNS drug candidates for the treatment of obesity

(2012) D J Heal et al.   INTERNATIONAL JOURNAL OF OBESITY

Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons

(2012) Marcelo O. Dietrich et al.   NATURE REVIEWS DRUG DISCOVERY

Melanocortin-4 Receptors Expressed by Cholinergic Neurons Regulate Energy Balance and Glucose Homeostasis

(2011) Jari Rossi et al.   Cell Metabolism

JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats

(2011) T. Hata et al.   DIABETES OBESITY & METABOLISM

Novel strategy for the use of leptin for obesity therapy

(2011) Charmaine S Tam et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile

(2011) E. Kim et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy

(2010) M A Valentino et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

(2010) Pradeep J. Nathan et al.   CNS Neuroscience & Therapeutics

Histamine H3Receptor as a Drug Discovery Target

(2010) Michael Berlin et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Histamine H3 Receptor and Eating Behavior

(2010) M. B. Passani et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Current and Future Drug Targets in Weight Management

(2010) Renger F. Witkamp   PHARMACEUTICAL RESEARCH

Reward, dopamine and the control of food intake: implications for obesity

(2010) Nora D. Volkow et al.   TRENDS IN COGNITIVE SCIENCES

Results of Roux-en-Y Gastric Bypass in Morbidly Obese vs Superobese Patients

(2009) Michel Suter   ARCHIVES OF SURGERY

Stimulation of Cholecystokinin-A Receptors With Gl181771X: A Failed Clinical Trial That Did Not Test the Pharmacogenetic Hypothesis for Reduction of Food Intake

(2009) AD Roses   CLINICAL PHARMACOLOGY & THERAPEUTICS

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

(2009) R Krishna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates

(2009) Eric A. Finkelstein et al.   HEALTH AFFAIRS

Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents

(2009) Nicola Santoro et al.   JOURNAL OF HYPERTENSION

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy

(2009) Eric Ravussin et al.   Obesity

Weight Loss, HbA1cReduction, and Tolerability of Cetilistat in a Randomized, Placebo-controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)

(2009) Peter Kopelman et al.   Obesity

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Modulation of Blood Pressure by Central Melanocortinergic Pathways

(2008) Jerry R. Greenfield et al.   NEW ENGLAND JOURNAL OF MEDICINE